579
Waning of Virological Benefits following Directly Administered ART among Drug Users: Results from a Randomized, Controlled Trial
D Smith-Rohrberg Maru, R Bruce, M Walton, S Springer, and Frederick Altice*
AIDS Prgm, Yale Univ Sch of Med, New Haven, CT, US
Background: HIV+ drug users have derived
less benefit from ART than others. While directly administered ART (DAART) has
demonstrated impressive biological benefits compared with self-administered
therapy among HIV+ drug users, the persistence of DAART following
transition to self-administered therapy has not been examined.
Methods: We conducted a community-based,
prospective, randomized controlled trial of 6 months of DAART compared with self-administered
therapy in New Haven, Connecticut. The primary outcome was the proportion of
subjects who achieved virological success at 6 months post-intervention,
defined as achieving either a ≥1.0 log10 reduction from
baseline or HIV-1 RNA <400 copies/mL. Secondary outcomes included the change
from baseline in HIV-1 RNA and CD4 lymphocyte count.
Results: At the end of 6 months, the DAART group (n =
88) was more likely to have a virological success (70.5% vs 54.7%, p = 0.02),
mean reduction in HIV-1 RNA level (1.16 log10 vs 0.29 log10 copies/mL;
p = 0.03) and a change in CD4 lympocyte count (+58.8 vs –24.0 cells/mL; p
= 0.002). After an additional 6 months of observation when all subjects
received medications as self-administered therapy, the DAART (n = 82) and self-administered
therapy (n = 52) arms did not differ on virological success (DAART 58.0% vs self-administered
therapy 56.6%, p = 0.64), mean reduction in log10 HIV-1 RNA (–0.79
vs –0.31 log10 copies/mL, p = 0.53), nor mean change in CD4
lymphocyte count (+60.2 vs –15.4 cells/mL, p = 0.12). In the
multivariate analysis, only high levels of social support significantly
predicted virological success.
Conclusions: This analysis, from the first randomized
controlled trial of DAART among active drug users, is the first to examine the
post-intervention effects of DAART. Failure to show the persistence of DAART at
improving virological outcomes suggests that further studies in HIV+
drug users should examine a longer DAART duration or incorporation of
self-efficacy or social support components, which may provide durability to
this otherwise effective intervention.
|